Sunday, October 4, 2015

Valeant’s Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers


By ANDREW POLLACK and SABRINA TAVERNISE via NYT Business Day http://ift.tt/1hiPwZ3
Posted by at
Labels: , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)